Security
HUTCHMED (China) Limited American Depositary Shares · HCM
HCMNASDAQotherCurrentCIK 1648257Updated Oct 6, 2026
Name history
Hutchison China MediTech Ltd · through Apr 29, 2021
HCM price & chart
Loading TradingView…
NASDAQ:HCM on TradingView ↗About the company
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,753,097,000Source | 1,274,196,000Source | 1,279,773,000Source | 1,029,445,000Source |
| Property, Plant and Equipment, NetUSD | 94,623,000Source | 92,498,000Source | 99,727,000Source | 75,947,000Source |
| GoodwillUSD | 3,112,000Source | 2,990,000Source | 3,064,000Source | 3,137,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 8,941,000Source | — | 21,000Source | 85,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 71,330,000Source | 153,958,000Source | 283,589,000Source | 313,278,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 126,750,000Source | 155,537,000Source | 116,894,000Source | 97,988,000Source |
| Inventory, NetUSD | 41,129,000Source | 50,400,000Source | 50,258,000Source | 56,690,000Source |
| Assets, CurrentUSD | 1,567,342,000Source | 1,066,555,000Source | 1,096,839,000Source | 839,888,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,027,000Source | 4,497,000Source | 4,665,000Source | 8,722,000Source |
| Other Assets, NoncurrentUSD | 20,092,000Source | 15,433,000Source | 14,675,000Source | 15,745,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 501,835,000Source | 502,343,000Source | 536,386,000Source | 392,575,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 87,233,000Source | 87,160,000Source | 87,126,000Source | 86,478,000Source |
| Retained Earnings (Accumulated Deficit)USD | -378,643,000Source | -833,172,000Source | -870,869,000Source | -971,481,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -4,532,000Source | -11,585,000Source | -8,163,000Source | -1,903,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,237,926,000Source | 759,929,000Source | 730,541,000Source | 610,367,000Source |
| Additional Paid in Capital, Common StockUSD | 1,533,868,000Source | 1,517,526,000Source | 1,522,447,000Source | 1,497,273,000Source |
| Liabilities and EquityUSD | 1,753,097,000Source | 1,274,196,000Source | 1,279,773,000Source | 1,029,445,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 315,775,000Source | 376,562,000Source | 403,027,000Source | 353,903,000Source |
| Operating Lease, Liability, CurrentUSD | 2,881,000Source | 2,925,000Source | 3,927,000Source | 3,708,000Source |
| Accounts Payable, CurrentUSD | 45,533,000Source | 42,521,000Source | 36,327,000Source | 71,115,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,852,000Source | 4,089,000Source | 2,860,000Source | 5,196,000Source |
| Deferred Income Tax Liabilities, NetUSD | 255,000Source | 2,990,000Source | 1,484,000Source | 2,710,000Source |
| Other Liabilities, NoncurrentUSD | — | 10,836,000Source | 11,346,000Source | 12,662,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 13,336,000Source | 11,924,000Source | 12,846,000Source | 26,503,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 1,367,275,000Source | 836,110,000Source | 886,336,000Source | 630,996,000Source |
| Deferred Revenue, NoncurrentUSD | — | 48,432,000Source | 69,480,000Source | — |
| Long-term Debt, Current MaturitiesUSD | 24,971,000Source | 23,372,000Source | 31,155,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 68,189,000Source | 59,434,000Source | 48,189,000Source | 18,104,000Source |
| Short-term InvestmentsUSD | 1,295,945,000Source | 682,152,000Source | 602,747,000Source | 317,718,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 457,732,000Source | 38,170,000Source | 101,094,000Source | -360,386,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 13,308,000Source | 12,341,000Source | 8,207,000Source | 8,664,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -28,862,000Source | 38,545,000Source | 21,336,000Source | 14,451,000Source |
| Increase (Decrease) in InventoriesUSD | -9,542,000Source | 772,000Source | -4,135,000Source | 21,213,000Source |
| Increase (Decrease) in Accounts PayableUSD | 3,012,000Source | 6,194,000Source | -32,542,000Source | 29,938,000Source |
| Deferred Income Tax Expense (Benefit)USD | -118,000Source | 5,308,000Source | 2,226,000Source | -3,563,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -64,657,000Source | 497,000Source | 219,258,000Source | -268,599,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -29,410,000Source | -96,060,000Source | -291,136,000Source | 296,588,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 14,148,000Source | 17,933,000Source | 32,612,000Source | 36,664,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | 36,064,000Source | 9,071,000Source | 48,084,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 7,836,000Source | -30,667,000Source | 48,660,000Source | -82,763,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -82,628,000Source | -129,631,000Source | -29,689,000Source | -64,264,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 71,330,000Source | 153,958,000Source | 283,589,000Source | 313,278,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,518,000Source | 2,509,000Source | 421,000Source | 150,000Source |
| Income Taxes Paid, NetUSD | 62,411,000Source | 3,587,000Source | 3,728,000Source | 18,891,000Source |
| Additional Financial Items | ||||
| Amortization of Debt Issuance CostsUSD | — | — | — | 18,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 1,367,275,000Source | 836,110,000Source | 886,336,000Source | 630,996,000Source |
| DepreciationUSD | 11,998,000Source | 12,070,000Source | 7,888,000Source | 8,327,000Source |
| Equity Method Investment, Other than Temporary ImpairmentUSD | — | — | — | 130,000Source |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | 476,896,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 21,000Source | -10,000Source | -86,000Source | -111,000Source |
| General and Administrative ExpenseUSD | 66,722,000Source | 64,296,000Source | 79,784,000Source | 92,173,000Source |
| GoodwillUSD | 3,112,000Source | 2,990,000Source | 3,064,000Source | 3,137,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 22,651,000Source | 46,469,000Source | 47,295,000Source | 49,753,000Source |
| Income Tax Expense (Benefit)USD | 63,610,000Source | 7,192,000Source | 4,509,000Source | -283,000Source |
| InterestExpenseNonoperatingUSD | 2,865,000Source | 2,872,000Source | — | — |
| Investment Income, InterestUSD | 49,877,000Source | 40,080,000Source | 36,145,000Source | 9,599,000Source |
| Net Income (Loss) Attributable to ParentUSD | 456,909,000Source | 37,729,000Source | 100,780,000Source | -360,835,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 823,000Source | 441,000Source | 314,000Source | 449,000Source |
| Nonoperating Income (Expense)USD | 60,955,000Source | 42,598,000Source | 39,933,000Source | -2,729,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 5,372,000Source |
| Operating Lease, Impairment LossUSD | — | 1,889,000Source | 2,088,000Source | — |
| Proceeds from Issuance of Common StockUSD | 1,578,000Source | 790,000Source | 5,094,000Source | 174,000Source |
| Stock or Unit Option Plan ExpenseUSD | 2,513,000Source | 3,069,000Source | 6,184,000Source | 6,736,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 548,512,000Source | 630,201,000Source | 837,999,000Source | 426,409,000Source |
| Cost of RevenueUSD | 336,349,000Source | 348,884,000Source | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | -39,160,000Source | -43,705,000Source | 18,375,000Source | -407,693,000Source |
| Income Tax Expense (Benefit)USD | 63,610,000Source | 7,192,000Source | 4,509,000Source | -283,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 823,000Source | 441,000Source | 314,000Source | 449,000Source |
| Net Income (Loss) Attributable to ParentUSD | 456,909,000Source | 37,729,000Source | 100,780,000Source | -360,835,000Source |
| Earnings Per Share, BasicUSD per share | 0.53Source | 0.04Source | 0.12Source | -0.43Source |
| Earnings Per Share, DilutedUSD per share | 0.52Source | 0.04Source | 0.12Source | -0.43Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 858,276,608Source | 855,351,683Source | 849,654,296Source | 847,143,540Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 872,891,120Source | 872,829,129Source | 869,196,348Source | 847,143,540Source |
| Interest Expense (non-operating)USD | 2,865,000Source | 2,872,000Source | — | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 587,672,000Source | 673,906,000Source | 819,624,000Source | 834,102,000Source |
| Current Income Tax Expense (Benefit)USD | 63,728,000Source | 1,884,000Source | 2,283,000Source | 3,280,000Source |
| General and Administrative ExpenseUSD | 66,722,000Source | 64,296,000Source | 79,784,000Source | 92,173,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 22,651,000Source | 46,469,000Source | 47,295,000Source | 49,753,000Source |
| Interest ExpenseUSD | — | — | 759,000Source | 652,000Source |
| Investment Income, InterestUSD | 49,877,000Source | 40,080,000Source | 36,145,000Source | 9,599,000Source |
| Labor and Related ExpenseUSD | 58,317,000Source | 69,079,000Source | 93,030,000Source | 119,306,000Source |
| Nonoperating Income (Expense)USD | 60,955,000Source | 42,598,000Source | 39,933,000Source | -2,729,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 5,372,000Source |
| Research and Development ExpenseUSD | 148,295,000Source | 212,109,000Source | 302,001,000Source | 386,893,000Source |
| Selling ExpenseUSD | 36,306,000Source | 48,617,000Source | 53,392,000Source | 43,933,000Source |
Filing attachments
hcm-ex99d1.htm · 6-K · 2026-09-29
Exhibit 99.1 Press Release HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer - Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy - - Application supported by SAFFRON, the first global Phase III trial to demonstrate statistically significant and clinically meaningful improvements in progression-free and o…
Read attachment ↗hcm-ex99d1.htm · 6-K · 2026-09-29
Exhibit 99.1 Press Release HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors - First-in-class KRAS-payload leveraging synchronized EGFR inhibition - Hong Kong, Shanghai & Florham Park, NJ - Monday, September 28, 2026: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced…
Read attachment ↗hcm-20260903xex99d1.htm · 6-K · 2026-09-03
Exhibit 99.1 HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy - Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 - - HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT / 12:30 p.m. BST / 7:30 p.m. HKT in English - Hong Kong, Shanghai & Florham Park, NJ - Thursday, September 3, 2026: HUTCHMED (China) Lim…
Read attachment ↗hcm-20260831xex99d1.htm · 6-K · 2026-08-31
EX-99.1 2 hcm-20260831xex99d1.htm EX-99.1 Exhibit 99.1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 (Incorporated in the Cayman Isl…
Read attachment ↗hcm-20260828xex99d1.htm · 6-K · 2026-08-28
Exhibit 99.1 Press Release HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma - Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China - Hong Kong, Shanghai & Florham Park, NJ - Friday, August 28, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug…
Read attachment ↗hcm-20260818xex99d1.htm · 6-K · 2026-08-18
Exhibit 99.1 Announcement pursuant to AIM Rule 17 Schedule 2(g) Update Hong Kong, Shanghai & Florham Park, NJ - Tuesday, August 18, 2026: HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX:13) (the “Company”, together with its subsidiaries, the “Group”) today provides the following update pursuant to Rule 17 Schedule 2(g) of the AIM Rules for Companies (the “AIM Rules”). The board of directors of the Company (the “Board”) was notified by Dr Dan Eldar, Chairman and Non-executive Director of the C…
Read attachment ↗